In Categories: Economic Impact

To truly change the course of the diabetes epidemic and reach our goal of reversing type 2 diabetes in 100 million people by 2025, we need help from partners who are as passionate as we are about bringing transformational healthcare solutions to patients. This is why we are so excited to announce that Virta is partnering with Accolade, a leading personalized advocacy and population health solution for employers and health plans.

The need for change in type 2 diabetes treatment has never been more apparent, as the economic burden has ballooned to over $400B. Despite significant investment, we aren’t seeing improvement in the individual targets for type 2 diabetes, according to a recent study in The Journal of American Medicine (JAMA). Diabetes is spiraling out of control, and creating devastating circumstances for individuals, families, and our economy.

Our partnership with Accolade brings us one step closer to changing this trend. For employees at our shared customers, access to the Virta Treatment will be that much easier. Accolade’s world-class expertise in delivering personalized health recommendations enables quick and easy access to the Virta Treatment for those who will benefit most.

Additionally, for those employers and health plans who already partner with Accolade but not Virta, adding the Virta Treatment to their diabetes portfolio will be a snap. And, because of Virta’s 100% fees-at-risk model (we only charge if we successfully achieve diabetes reversal metrics), payers can bring type 2 diabetes reversal to their populations nearly risk-free.

This partnership is a win for patients and payers alike. Earlier this year, we announced the publication of our two-year clinical trial results, which showed that at two years, 67% of medications were removed across the population, including an 81% reduction in usage of insulin. This coincided with a 0.9 HbA1c decrease, meaning that patients got healthier while being less reliant on medications.

Almost half of all Virta patients who began the clinical trial on diabetes-specific medications were able to discontinue all of their medications at two years.These results on their own are transformational, but what has been even more encouraging is that our commercial results equal and in most cases exceed our clinical outcomes. Because of our technology and data-science underpinning, with each patient we treat, we are able to incorporate what we learn back into our overall approach.

It is this approach that contributes to the life-changing outcomes experienced by our wonderful patients like Guy, Andrea, and Patrick. Each has their own unique and heartwarming story, joining the many thousands of others who have chosen to make type 2 diabetes and a life full of medications a relic of their past.

From companies like Comcast and Lowe’s to leading health systems like Temple University Health, Accolade serves organizations committed to providing the most progressive and effective benefits to their employees and members. We couldn’t be more excited to help them bring the health and economic benefits of diabetes reversal to their customers, and are looking forward to the many reversal stories to come.

One Comment

  1. Avatar

    It wouldn’t do to over-state that the same people who supplement the sugar production in America are also people who have their fingers in Big Pharma and profit on the sale of insulin. The FDA allows sugar to be put in every processed foodstuff produced in USA, the government also regulates the FDA and Big Pharma lobbies the FDA. Is there a coorelation or am I the only one who sees the mystery of this link?

    Reply

Leave a reply

Your email address will not be published.